Compare DuPont de Nemours Inc (DD) vs Expensify Inc (EXFY) Price & Performance

DuPont (DD) trades at $131.08, down 1.65% on the day, with neutral technical signals from moving averages and oscillators. The company shows mixed fundamentals with recent earnings beats but declining revenue from $12.4B in 2024 to $6.85B in 2025, resulting in a net loss of $779M. Analyst sentiment remains positive with 58.5% buy ratings, though the consensus price target of $95 suggests caution. Recent developments include new product launches in sugar separation technology and Tyvek innovations, alongside ongoing PFAS litigation settlements.

The outlook for DD hinges on margin recovery and growth in key sectors like healthcare and water technologies, but investors face risks from legal liabilities, volatile cash flows, and high P/E valuation. Institutional activity shows mixed signals with both position reductions and significant increases, reflecting uncertainty about near-term performance amid structural growth opportunities.

Expensify (EXFY) trades at $2.27, up 1.79% with a neutral technical signal. The company shows mixed fundamentals with revenue stabilizing around $140M but persistent net losses. Recent quarters show earnings improvement with two beats, while analyst consensus is bullish with a $13.75 price target. Business developments include AI integrations and European expansion of corporate card offerings.

The outlook remains speculative given negative profitability metrics, though cash flow improvements and strategic partnerships provide potential catalysts. Key risks include competitive pressure in expense management and the challenge of achieving sustainable profitability. The significant gap between current price and analyst targets suggests upside potential if execution improves.